Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (6720)	7/18/1998 6:54:00 PM
From: Bluegreen	Respond to of 17367

If Neuprex didn't work I would think the British would not have enrolled so many patients during their epidemic of Meningococcemia. I would imagine that at St. Mary's in West London, they have seen more rapid improvement of clinical and lab reports in Neuprex treated patients. But you say wait a minute, it is double blinded placebo controlled study. Well, I answer if the drug really works, you will see it in the lab and clinical picture. Wasn't there some discussion about an Adult study in London? Also I noticed in the Xoma FAQ that Xoma may get European approval before U.S. approval if there is any approval at all. Another thing that interests me is the hiring of people at Xoma. Mind you all of the above are my opinions but I would think the British would stop such lion's share of enrollment if they didn't think Neuprex was improving patient outcome. I am new here Mr. Wohanka, what did you mean by the hooligan comment?